Matthew Stenger

1 week ago | ascopost.com | Matthew Stenger

In a study reported in The Lancet Oncology, Neupane et al explored the question of whether cancer treatment and genetic predisposition are primary contributors to the risk of subsequent neoplasms (SNs) in long-term survivors of childhood cancers.

1 week ago | ascopost.com | Matthew Stenger

In a phase III trial (PANOVA-3) reported in the Journal of Clinical Oncology, Babiker et al examined the survival benefit of using tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in patients with unresectable locally advanced pancreatic adenocarcinoma.

1 week ago | ascopost.com | Matthew Stenger

In a phase III trial (NSABP B-51–RTOG 1304) reported in The New England Journal of Medicine, Mamounas et al examined regional nodal irradiation for activity in preventing invasive breast cancer recurrence or death from breast cancer in patients who had negative axillary nodes after neoadjuvant chemotherapy. Study DetailsThe international trial was activated in August 2013 and closed to enrollment in December 2020.

1 week ago | ascopost.com | Matthew Stenger

In a phase III trial (BRUIN CLL-321) reported in the Journal of Clinical Oncology, Sharman et al compared treatment outcomes with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib vs investigator choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in patients with relapsed or refractory, covalent BTK inhibitor–pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

1 week ago | ascopost.com | Matthew Stenger

In a phase II trial (EBIN) reported in The Lancet Oncology, Robert et al investigated the survival benefit of adding induction encorafenib/binimetinib to nivolumab/ipilimumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutation.